Monopar Therapeutics financials at a glance

+ Portfolio

The revenue of Monopar Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -0.61 Dollars per share in 2023, which was 13.7 lower than 2021. And about 0 billion Dollars are reported as free cash flow in the financials of Monopar Therapeutics 2023. No dividends were paid to the shareholders of the Monopar Therapeutics stock NasdaqCM:MNPR in the financial year 2023.

$0.00M

Revenue

$-0.83

Earnings Per Share

0.00%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-0.83

Gross Margin %

0.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.71	$-0.83	$-0.73	$-0.58	$-0.45
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0
Sha.	Shares	N/AM	13.19M	12.6M	12.57M	10.62M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.57	$-0.57	$-0.59	$-0.43	$-0.32

Monopar Therapeutics financials at a glance

Financials

Discover